ZBD | $40,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Asymmetric Security | $4,200,000 | (Jan 23, 2026)
Sedivention GmbH
Germany
- Straßlach-Dingharting
- 03/12/2024
- Pre-Seed
- $839,204
Sedivention develops a break-through, widely applicable, device for interventional obesity therapy. Hunger is transmitted from the stomach to the brain by the gastric trunks of the vagal nerve. Sedivention is developing a cryo-balloon freezing the gastric branches of the vagal nerve from inside the stomach, in a procedure comparable to gastroscopy. The ambulatory intervention takes approximately 20 min. The costs of the intervention are far below costs of bariatric surgery without surgical morbidity and complications. In brief: Sedivention develops the first long-term effective, scalable therapy for obesity: No scars, no pain, no surgical complications, no access barriers at an affordable price. Obesity causes over 400.000 deaths yearly in the US alone and costs of more than 2.0 trillion $US worldwide. According to the WHO obesity Atlas 2022, there will be 1 billion obese persons worldwide in 2030.
- Industry Medical Equipment Manufacturing
- Website https://www.sedivention.com/
- LinkedIn https://www.linkedin.com/company/sedivention-gmbh/
Related People
Ute Dr. med. NollertFounder
Germany -
Straßlach-Dingharting, Bavaria
I am a consultant anesthesiologist, affiliated to the Sana Klinik München. In 2021, I founded sedivention, a medtech company, that develops a device for interventional obesity therapy.
Cubby | $63,000,000 | (Jan 23, 2026)
Cambio | $18,000,000 | (Jan 23, 2026)
Cork Protocol | $5,500,000 | (Jan 23, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)
Mendra | $82,000,000 | (Jan 23, 2026)
Artie Technologies | $12,000,000 | (Jan 23, 2026)
Antidote Legal | $5,000,000 | (Jan 23, 2026)
One to One Health | $12,000,000 | (Jan 22, 2026)